Letters Section Editor: Jody W. Zylke, MD, Senior Editor.
Author Affiliation: Division of Cardiology, West China Hospital, Sichuan, Chengdu, China (firstname.lastname@example.org).
To the Editor: Dr Najjar and colleagues1 reported that infarct size, assessed by cardiac magnetic resonance imaging (CMR) performed 2 to 6 days after study medication administration, did not differ between the erythropoietin and placebo groups. However, I am concerned whether infarct size is the optimal primary end point. It seems premature to replace traditional hard end points with infarct size as a surrogate end point to evaluate therapeutic efficacy of new drugs.
Chen Y. Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction. JAMA. 2011;306(7):705-706. doi:10.1001/jama.2011.1144